LightIntegra Technology

About LightIntegra Technology

LightIntegra Technology Inc. operates as a medical diagnostics company, concentrating on enhancing the safety and effectiveness of platelet transfusions. The company was established in 2008, spinning out from the research and development labs of Canadian Blood Services. This was driven by the work of research scientist Dr. Elisabeth Maurer, who founded the company and serves as its Chief Technology Officer. Dr. Maurer's extensive research into platelet function led to a key discovery utilizing dynamic light scattering to assess platelet quality, which became the foundation of the company's core technology.

The company's flagship product is ThromboLUX, a diagnostic test platform designed to evaluate the quality of platelet concentrates before transfusion. The system addresses the significant issue of platelet refractoriness, where patients, particularly those with cancer, fail to get the expected benefit from a transfusion. The business targets healthcare institutions, such as hospitals and blood banks, aiming to reduce healthcare costs and improve patient outcomes by ensuring the right quality of platelets is used for the right patient. For instance, non-activated platelets are optimal for cancer patients, while activated platelets are better suited for trauma or surgery patients. Revenue is generated through the sale of the ThromboLUX system and associated products.

ThromboLUX employs dynamic light scattering (DLS) to analyze particles in a platelet sample, determining their size and distribution within five minutes. This rapid, non-invasive test does not require reagents or sample dilution. It provides a comprehensive analysis by measuring microparticle content, which indicates platelet stress and viability. By identifying platelet concentrates that are less likely to cause adverse reactions, ThromboLUX allows clinicians to select the most appropriate units for transfusion, potentially reducing the number of ineffective transfusions, shortening hospital stays, and lowering the risk of mortality associated with platelet refractoriness. The company has received significant funding, including a Series A round of $5.3 million USD in 2019, to support commercialization efforts, particularly in the United States.